FDA points out shortcomings in Ascendis application
The market clearance decision for a drug candidate could be delayed in the United States, Ascendis Pharma warns.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
No later than April 30, Ascendis Pharma was meant to have received answer from the US Food and Drug Administration’s (FDA) concerning the market clearance of TransCon PTH.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA sets deadline for Ascendis Pharma drug decision
For subscribers
Ascendis Pharma submits candidate for US market approval
For subscribers
